Malignant hypertension in association with primary aldosteronism

Blood Pressure

Volumn 5, Issue 4, 1996, Pages 250-254

  Zarifis, John ^a   Lip, Gregory Y H ^a   Leatherdale, Brian ^a   Beevers, Gareth ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Conn's syndrome; hyperaldosteronism; malignant hypertension

Indexed keywords

ALDOSTERONE; RENIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HYPERTENSION; HYPOKALEMIA; MALE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

EID: 0030018544     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609079679     Document Type: Article

References (17)

1. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-71.
2. Ferriss JB, Beevers DG, Brown JJ, Davies DL, Fraser R, Lever AF et al. Clinical biochemical and pathological features of low renin ("primary") hyperaldosteronism. Am Heart J 1978; 95: 375-88.
3. Brown JJ, Chinn RH, Dusterdieck GO. Hypertension and hyperaldosteronism with low plasma renin concentration: analysis of a series of eighty patients. Proc Roy Soc Med 1969, 62: 1259-60.
4. Laragh JH, Sealey JE, Atlas SA. The renin system for understanding human hypertension :evidence for blood pressure control by bipolar vasoconstriction-volume mechanism.Protein as a determinant of renin secretion. Clin Exp Hypertens 1982; A4: 2303-37.
5. Kaplan NM. Primary aldosteronism with malignant hypertension. N Engl J Med 1963; 269: 1283-6.
6. Del Greco F, Dolkart R, Skom J, Method H. Association of accelerated [malignant] hypertension in a patient with primary aldosteronism. J Clin Endocrinol 1966, 26: 808-14.
7. Aloia JF, Beutow G. Malignant hypertension with aldosterone producing adenoma . Am J Med Sci 1974, 268: 241-5.
8. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Figgord RW et al. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74: 641-51.
9. Sunman W, Rothwell M, Sever PS. Conn's syndrome can cause malignant hypertension. J Hum Hypertens 1992; 6: 75-6.
10. Yu Suk-Hee, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: Aetiology and outcome in 83 patients. Clin Exp Theory Prac 1986; A: 8: 1211-30.
11. Webster J, Petrie JC, Jeffers TA, Lovel HG. Accelerated hypertension - patterns of mortality and clinical factors affecting outcome in treated patients.Q J Med 1993; 86: 485-93.
12. Lip GYH, Beevers M, Beevers DG. The failure of malignant hypertension to decline: A survey of 24 years experience. J Hypertens 1994; 12: 1297-305.
13. Keith NM, Wagener HP, Barker NW. Same different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 268: 336-45.
14. Vaughan NJA, Slater JDH, Lightman SL. The diagnosis of primary hyperaldosteronism. Lancet 1981; i: 120-5.
15. Brill GC, Creamer B, Mills IH, Pullan JM. Hyperaldosteronism: report of a case. BMJ 1960; 2: 990-91.
16. Luetscher JA. Primary hyperaldosteronism: observations in six cases and review of diagnostic procedures. Medicine (Baltimore) 1964; 43: 437-57.
17. McAllister RG, van Way CW, Dayani K et al. Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res 1971; 28/29 (Suppl 2): 177-93.